This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.

Insights

The latest news and events at Maples Teesdale

| 2 minute read

Adaptive Reuse for Life Sciences: From Workaround to Strategic Imperative

At the Property Week and Construction News Life Sciences Conference yesterday, I had the pleasure of moderating a panel on a topic that’s increasingly front and centre for developers, investors, and real estate professionals alike: adaptive reuse as a strategy for delivering lab space, particularly in urban locations.

The UK’s life sciences sector continues to grow, but the real estate needed to support it hasn’t kept pace in all parts of the sector. In key urban centres, demand for fitted lab space far outstrips supply — and while the momentum is there, the focus has shifted toward cost-effective and deliverable solutions, particularly for early-stage and Series A-funded businesses.

That’s where adaptive reuse comes in. And the message from our panellists — from major investors and platform operators to those actively delivering space — was clear: repurposing isn’t a fallback. It’s fast becoming the model of choice.

Why is adaptive reuse gaining traction?

1. Occupiers need more than space — they need usability
The life sciences sector is unique in that many occupiers, especially early-stage biotech and medtech firms, lack the time, money, or in-house expertise to manage complex refits. What they need is plug-and-play space that’s ready to support R&D from day one. Adaptive reuse schemes that deliver lab-ready units — rather than shell-and-core — are proving particularly attractive.

2. Location remains non-negotiable
The “Golden Triangle” of London, Oxford, and Cambridge is still very much in demand, and occupiers prioritise proximity to research institutions, access to talent, and the vibrancy of an urban ecosystem. Being embedded in a collaborative environment is as important as the physical space itself.

3. Reuse can be competitive on both cost and carbon
In constrained urban settings, the cost of demolition and new build can equal — or even exceed — that of a high-quality conversion. Add to that the ESG advantages of retaining embodied carbon and minimising construction waste, and reuse becomes not just financially viable but also environmentally responsible.

Challenges — and how to overcome them

Of course, adaptive reuse isn’t always simple. Lab conversions bring specific technical challenges: vibration sensitivity, floor-to-ceiling height requirements, structural loading, and servicing logistics all require careful consideration. But, as our panellists stressed, these issues are manageable — if the base building is right.

The conversion of Victoria House in Bloomsbury was a case in point. Its generous floor-to-ceiling heights, pre-existing atriums (ideal for ductwork), and robust concrete frame made it a strong candidate for life sciences use. Thoughtful design and early engagement with technical consultants made the difference.

Looking ahead

As legal and real estate professionals, we’re being asked to think more creatively — and strategically — about how to unlock value from existing assets. Adaptive reuse sits at the intersection of that challenge: part planning, part engineering, part ecosystem-building.

What stood out most in this panel was the sense that the sector is maturing. Occupiers are more discerning, capital is more selective, and delivery risks are under closer scrutiny. In that context, reuse isn’t a compromise — it might be the smarter route forward.

If you’re exploring lab reuse opportunities — whether from a legal, planning or delivery angle — we would be happy to discuss the challenges and what’s working in practice.

celebrate outstanding projects, pioneering technologies and visionary teams that are shaping the future of science and technology estates.”

Subscribe to our latest insights by topic here

Tags

chris xitsas, commercial real estate, life sciences, esg, articles, research clusters, lab space, biotech, medtech